CA3217818A1 - Analytical hplc - Google Patents

Analytical hplc Download PDF

Info

Publication number
CA3217818A1
CA3217818A1 CA3217818A CA3217818A CA3217818A1 CA 3217818 A1 CA3217818 A1 CA 3217818A1 CA 3217818 A CA3217818 A CA 3217818A CA 3217818 A CA3217818 A CA 3217818A CA 3217818 A1 CA3217818 A1 CA 3217818A1
Authority
CA
Canada
Prior art keywords
mobile phase
organic solvent
radiopharmaceutical
acid
hplc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3217818A
Other languages
English (en)
French (fr)
Inventor
Alan Clarke
Hendrik Petrus ENGELBRECHT
Julian Grigg
Imtiaz Ahmed Khan
Kristine WIKENE
Graeme Mcrobbie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GE Healthcare Ltd
Original Assignee
GE Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GE Healthcare Ltd filed Critical GE Healthcare Ltd
Publication of CA3217818A1 publication Critical patent/CA3217818A1/en
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/26—Conditioning of the fluid carrier; Flow patterns
    • G01N30/28—Control of physical parameters of the fluid carrier
    • G01N30/34—Control of physical parameters of the fluid carrier of fluid composition, e.g. gradient
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/0093—Radioactive materials
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N2030/022—Column chromatography characterised by the kind of separation mechanism
    • G01N2030/027—Liquid chromatography
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
    • G01N2030/884—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample organic compounds
    • G01N2030/8845—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample organic compounds involving halogenated organic compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
    • G01N2030/8859—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample inorganic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
CA3217818A 2021-04-26 2022-04-26 Analytical hplc Pending CA3217818A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2105950.6 2021-04-26
GBGB2105950.6A GB202105950D0 (en) 2021-04-26 2021-04-26 Analytical HPLC
PCT/EP2022/061004 WO2022229155A1 (en) 2021-04-26 2022-04-26 Analytical hplc

Publications (1)

Publication Number Publication Date
CA3217818A1 true CA3217818A1 (en) 2022-11-03

Family

ID=76193425

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3217818A Pending CA3217818A1 (en) 2021-04-26 2022-04-26 Analytical hplc

Country Status (12)

Country Link
US (1) US20240302338A1 (enExample)
EP (1) EP4330662B1 (enExample)
JP (1) JP2024518319A (enExample)
KR (1) KR20240000562A (enExample)
CN (1) CN117222890A (enExample)
AU (1) AU2022264815A1 (enExample)
CA (1) CA3217818A1 (enExample)
ES (1) ES3050308T3 (enExample)
GB (1) GB202105950D0 (enExample)
IL (1) IL307946A (enExample)
PL (1) PL4330662T3 (enExample)
WO (1) WO2022229155A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201915206D0 (en) 2019-10-21 2019-12-04 Ge Healthcare Ltd Use of cyclodextrins as a radiostabilizer
CN119688861A (zh) * 2024-11-29 2025-03-25 中国辐射防护研究院 一种生物样本中18f-psma-1007放化纯的液相色谱分析方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5300280A (en) * 1992-02-14 1994-04-05 Mallinckrodt Medical, Inc. Stabilized radiopharmaceutical kits
ES2398393T3 (es) * 2002-03-01 2013-03-15 Dyax Corp. Péptidos de unión a KDR y a VEGF/KDR y su uso en diagnóstico y terapia
JP4942953B2 (ja) * 2005-06-30 2012-05-30 サントリーホールディングス株式会社 プロシアニジンの分析方法
US8214159B2 (en) * 2008-12-04 2012-07-03 Siemens Medical Solutions Usa, Inc. Apparatus and method for automated quality control
GB201013808D0 (en) * 2010-08-18 2010-09-29 Ge Healthcare Ltd Peptide radiotracer compositions
EP2450332A1 (en) * 2010-10-22 2012-05-09 Bayer Pharma Aktiengesellschaft Compounds for use in Imaging, diagnosing and/or treatment of diseases of the central nervous system (F-D2-Deprenyl)
GB201202420D0 (en) * 2012-02-13 2012-03-28 Ge Healthcare Ltd Radiotracer compositions
CN104718299B (zh) * 2012-08-13 2024-02-06 通用医院公司 用于线粒体复合物i的定量定位的系统和方法
GB201303830D0 (en) * 2013-03-04 2013-04-17 Univ Glasgow Methods,unit and device relating to the manufacture,processing,synthesising or screening of radiopharmaceutical compositions
GB201418893D0 (en) * 2014-10-23 2014-12-10 Univ Hull Monolithic body
GB201805253D0 (en) * 2018-03-29 2018-05-16 Ge Healthcare Ltd Ip Solid phase extraction
CN111333638A (zh) * 2020-03-17 2020-06-26 四川大学华西医院 18f标记的异喹啉并哒嗪酮类化合物及其合成方法和应用

Also Published As

Publication number Publication date
KR20240000562A (ko) 2024-01-02
EP4330662A1 (en) 2024-03-06
EP4330662B1 (en) 2025-09-03
PL4330662T3 (pl) 2025-11-12
JP2024518319A (ja) 2024-05-01
IL307946A (en) 2023-12-01
ES3050308T3 (en) 2025-12-19
CN117222890A (zh) 2023-12-12
US20240302338A1 (en) 2024-09-12
WO2022229155A1 (en) 2022-11-03
EP4330662C0 (en) 2025-09-03
AU2022264815A1 (en) 2023-10-26
GB202105950D0 (en) 2021-06-09

Similar Documents

Publication Publication Date Title
Tshibangu et al. Automated GMP compliant production of [18F] AlF-NOTA-octreotide
EP4330662B1 (en) Analytical hplc
Gustafsson et al. Combined PET and microdialysis for in vivo estimation of drug blood-brain barrier transport and brain unbound concentrations
Ogawa et al. Preparation and evaluation of an astatine-211-labeled sigma receptor ligand for alpha radionuclide therapy
Meisenheimer et al. Ethanol effects on 68Ga-radiolabelling efficacy and radiolysis in automated synthesis utilizing NaCl post-processing
Valtorta et al. [18F](2 S, 4 R)-4-Fluoroglutamine as a New Positron Emission Tomography Tracer in Myeloma
CA2672262C (en) Radioactive diagnostic imaging agent
HK40109526B (en) Analytical hplc
HK40109526A (en) Analytical hplc
JP7036543B2 (ja) 腫瘍イメージング剤、及びホウ素中性子捕捉療法用腫瘍治療剤
Sadeghpour et al. Evaluation of radiochemical purities of some radiopharmaceuticals in Shiraz Namazi teaching hospital
JPWO2008056481A1 (ja) 放射性画像診断剤
Wadsak et al. 18F fluoroethylations: different strategies for the rapid translation of 11C-methylated radiotracers
EP3339309B1 (en) Radioactive halogen-labeled pyrido[1,2-a]benzimidazole derivative compound
JP2025523821A (ja) 標的分子イメージングのための銅の放射性医薬組成物
Pehlivanoglu et al. Development and validation of a UV-Radio-HPLC method to assess chemical and radiochemical purity of [68Ga] Ga-PSMA-11
CN110382513B (zh) 用于衰老的PET成像的放射性标记的β-半乳糖苷酶底物
KR101850479B1 (ko) [18F]플루오로-도파의 중성 pH 안정화 방법
US8802053B2 (en) Radio-methyl vorozole and methods for making and using the same
Passannante et al. Pharmacokinetic Evaluation of New Drugs Using a Multi-Labelling Approach and PET Imaging: Application to a Drug Can-didate with Potential Application in Neuromuscular Disorders. Biomedicines 2023, 11, 253
JP6527736B2 (ja) 放射性医薬組成物
Lindner et al. An automated liquid chromatographic plasma analysis of amino acids used in combination with positron emission tomography (PET) for determination of in vivo plasma kinetics
Nakao et al. 1-Minute quality control tests for positron emission tomography radiopharmaceuticals
WO2017014599A9 (ko) [18f]플루오로-도파의 방사화학적 순도를 안정화시키는 조성물 및 이의 제조방법
JP5544550B2 (ja) ポジトロン断層撮影法および該方法に用いるポジトロン放出化合物

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250324

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250808

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20260317

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20260317

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260317

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260320

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260320

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260325

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20260325

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260325

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260325

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260325

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260325